Rationale and methods of the cardiometabolic valencian study (escarval-risk) for validation of risk scales in mediterranean patients with hypertension, diabetes or dyslipidemia
1 University Miguel Hernandez. Department of Clinical Medicine. San Juan de Alicante, Spain
2 University of Valencia. Department of Medicine. Valencia, Spain
3 University A Coruña. A Coruña, Spain
4 Unión de Mutuas. Castellón, Spain
5 Centro de Salud Beniganim. Valencia, Spain
6 Centro de Salud Benimaclet. Valencia, Spain
7 ESCARVAL Project. Valencia, Spain
8 Director of Programme Management WHO Regional Office for Europe. Copenhagen, Denmark
9 Department of Health; Valencia Government. Valencia, Spain
10 Loyola University of Chicago. Stricht School of Medicine. Department of Preventive Medicine and Epidemiology. Chicago, USA
BMC Public Health 2010, 10:717 doi:10.1186/1471-2458-10-717Published: 22 November 2010
The Escarval-Risk study aims to validate cardiovascular risk scales in patients with hypertension, diabetes or dyslipidemia living in the Valencia Community, a European Mediterranean region, based on data from an electronic health recording system comparing predicted events with observed during 5 years follow-up study.
A cohort prospective 5 years follow-up study has been designed including 25000 patients with hypertension, diabetes and/or dyslipidemia attended in usual clinical practice. All information is registered in a unique electronic health recording system (ABUCASIS) that is the usual way to register clinical practice in the Valencian Health System (primary and secondary care). The system covers about 95% of population (near 5 million people). The system is linked with database of mortality register, hospital withdrawals, prescriptions and assurance databases in which each individual have a unique identification number. Diagnoses in clinical practice are always registered based on IDC-9. Occurrence of CV disease was the main outcomes of interest. Risk survival analysis methods will be applied to estimate the cumulative incidence of developing CV events over time.
The Escarval-Risk study will provide information to validate different cardiovascular risk scales in patients with hypertension, diabetes or dyslipidemia from a low risk Mediterranean Region, the Valencia Community.